1. Ferreira, R. J. O. et al. The controversy of using PGA to define remission in RA. Nat. Rev. Rheumatol.
https://doi.org/nrrheum.2018.35
(2018).
2. van Tuyl, L. H. D. & Boers, M. Remission — keeping the patient experience front and centre. Nat. Rev. Rheumatol. 13, 573–574 (2017).
3. Ferreira, R. J. O. et al. Suppressing inflammation in rheumatoid arthritis: does patient global assessment blur the target? A practice-based call for a paradigm change. Arthritis Care Res.
https://doi.org/10.1002/acr.23284
(2017).
4. Boers, M. et al. World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. J. Rheumatol. Suppl. 41, 86–89 (1994).
5. Tugwell, P. & Boers, M. Developing consensus on preliminary core efficacy endpoints. J. Rheumatol. 20, 555–556 (1993).